A couple of months ago, I read an SA article about Harvard Bioscience (HBIO) that posited there would be a significant upside move in price related to its spin-off of Harvard Apparatus Regenerative Technology (HART). The basis for the bullish thesis rested on the expectation that the market would respond enthusiastically to a new solo player in regenerative medicine. The author's view seemed reasonable in light of the bullish reception Organovo (ONVO) received when it up-listed on July 9.
I was already aware of HART because it was on deck to price its shares for an IPO back in the spring, but pulled back. It formally withdrew its S-1 on May...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: